WallStSmart

Globus Medical (GMED)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 1107% more annual revenue ($35.48B vs $2.94B). GMED leads profitability with a 18.3% profit margin vs 13.0%. MDT appears more attractively valued with a PEG of 1.50. GMED earns a higher WallStSmart Score of 74/100 (B).

GMED

Strong Buy

74

out of 100

Grade: B

Growth: 7.3Profit: 7.0Value: 10.0Quality: 7.8
Piotroski: 4/9Altman Z: 3.88

MDT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 7.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

GMEDUndervalued (+51.9%)

Margin of Safety

+51.9%

Fair Value

$183.46

Current Price

$87.35

$96.11 discount

UndervaluedFair: $183.46Overvalued
MDTSignificantly Overvalued (-255.7%)

Margin of Safety

-255.7%

Fair Value

$24.34

Current Price

$87.89

$63.55 premium

UndervaluedFair: $24.34Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GMED4 strengths · Avg: 8.5/10
Altman Z-ScoreHealth
3.8810/10

Safe zone — low bankruptcy risk

Price/BookValuation
2.6x8/10

Reasonable price relative to book value

Operating MarginProfitability
24.4%8/10

Strong operational efficiency at 24.4%

Revenue GrowthGrowth
25.7%8/10

Revenue surging 25.7% year-over-year

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$110.62B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.30B8/10

Generating 2.3B in free cash flow

Areas to Watch

GMED2 concerns · Avg: 4.0/10
PEG RatioValuation
1.734/10

Expensive relative to growth rate

EPS GrowthGrowth
4.4%4/10

4.4% earnings growth

MDT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : GMED

The strongest argument for GMED centers on Altman Z-Score, Price/Book, Operating Margin. Profitability is solid with margins at 18.3% and operating margin at 24.4%. Revenue growth of 25.7% demonstrates continued momentum.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.

Bear Case : GMED

The primary concerns for GMED are PEG Ratio, EPS Growth.

Bear Case : MDT

The primary concerns for MDT are EPS Growth.

Key Dynamics to Monitor

GMED profiles as a growth stock while MDT is a value play — different risk/reward profiles.

GMED carries more volatility with a beta of 1.07 — expect wider price swings.

GMED is growing revenue faster at 25.7% — sustainability is the question.

MDT generates stronger free cash flow (2.3B), providing more financial flexibility.

Bottom Line

GMED scores higher overall (74/100 vs 56/100), backed by strong 18.3% margins and 25.7% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Globus Medical

HEALTHCARE · MEDICAL DEVICES · USA

Globus Medical, Inc., a medical device company, develops and markets healthcare solutions for patients with musculoskeletal disorders. The company is headquartered in Audubon, Pennsylvania.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?